This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Toll-like receptors in the pathogenesis of human B cell malignancies
Journal of Hematology & Oncology Open Access 12 August 2014
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Hallek M, Cheson BD, Catovsky D, Caligaris-Cappio F, Dighiero G, Döhner H et al. Guidelines for the diagnosis and treatment of CLL. Blood 2008; 111: 5446–5456.
Tesniere A, Apetoh L, Ghiringhelli F, Joza N, Panaretakis T, Kepp O et al. Immunogenic cancer cell death: a key-lock paradigm. Curr Opin Immunol 2008; 20: 504–511.
Spaner DE, Foley R, Galipeau J, Bramson J . Obstacles to effective Toll-like receptor agonist therapy for hematologic malignancies. Oncogene 2008; 27: 208–217.
Shi Y, White D, He L, Miller RL, Spaner DE . TLR-7 tolerizes malignant B cells and enhances killing by cytotoxic agents. Cancer Res 2007; 67: 1823–1831.
Spaner DE, Masellis A . TLR agonists in the treatment of CLL. Leukemia 2007; 21: 53–60.
Dummer R, Hauschild A, Becker JC, Grob JJ, Schadendorf D, Tebbs V et al. An exploratory study of systemic administration of the TLR-7 agonist 852A in patients with refractory metastatic melanoma. Clin Cancer Res 2008; 14: 856–864.
Dudek AZ, Yunis C, Harrison LI, Kumar S, Hawkinson R, Cooley S et al. First in human phase I trial of 852A, a novel systemic TLR-7 agonist, to activate innate immune responses in patients with advanced cancer. Clin Cancer Res 2007; 13: 7119–7125.
Raphael B, Andersen JW, Silber R, Oken M, Moore D, Bennett J et al. Comparison of chlorambucil and prednisone versus cyclophosphamide, vincristine, and prednisone as initial treatment for CLL. J Clin Oncol 1991; 9: 770–776.
Tomic J, White D, Shi Y, Mena J, Hammond C, He L et al. Sensitization of IL-2 signaling through TLR-7 enhances B lymphoma cell immunogenicity. J Immunol 2006; 176: 3830–3839.
Acknowledgements
This study was supported by grants from 3M Pharmaceuticals, Ontario Institute of Cancer Research (OICR) (#07Nov-61), Canadian Institutes of Health Research (CIHR) (MOP-79389) and the National Cancer Institute of Canada (NCIC), with funds from the Terry Fox Foundation (#018005) (to DS). We thank Drs Lisa Hicks for help with initial protocol development. This paper is dedicated to the memory of Dr Anna Masellis.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Spaner, D., Shi, Y., White, D. et al. A phase I/II trial of TLR-7 agonist immunotherapy in chronic lymphocytic leukemia. Leukemia 24, 222–226 (2010). https://doi.org/10.1038/leu.2009.195
Published:
Issue Date:
DOI: https://doi.org/10.1038/leu.2009.195
This article is cited by
-
Toll-like receptors in the pathogenesis of human B cell malignancies
Journal of Hematology & Oncology (2014)
-
Roles of toll-like receptors in Cancer: A double-edged sword for defense and offense
Archives of Pharmacal Research (2012)
-
The novel antisense Bcl-2 inhibitor SPC2996 causes rapid leukemic cell clearance and immune activation in chronic lymphocytic leukemia
Leukemia (2011)
-
Aberrant O-GlcNAcylation characterizes chronic lymphocytic leukemia
Leukemia (2010)